Davita Inc vs Ecopetrol SA — how do they compare? Davita Inc trades at $232 (market cap $14.92B), while Ecopetrol SA trades at $16.24 (market cap $29.46B). The key difference: Ecopetrol SA is the larger of the two by market cap, and Ecopetrol SA pays a 4.02% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | EC | |
|---|---|---|
Market Cap | $14.92B | $29.46B |
Sector | Health | Energy |
52-Week High | $235.71 | $16.58 |
52-Week Low | $103.87 | $8.29 |
Enterprise Value | $27.47B | $57.24B |
Dividend Yield | — | 4.02% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Ecopetrol (EC) trades at $15.88, up 1.93% with a bullish technical signal from moving averages. The stock shows mixed earnings performance with recent misses but maintains solid profitability with 8.76% net margin and 13.01% ROE. Recent positive developments include a collective bargaining agreement with workers and S&P credit rating affirmation. Valuation appears reasonable with P/E of 11.31 and P/S of 0.99, trading near analyst consensus target of $14.63.
EC presents a balanced opportunity with attractive valuation metrics and stable dividend yield, though facing revenue decline from $159.6B in 2022 to $119.7B in 2025. Key risks include ongoing revenue pressure, debt levels at 42.51% of assets, and oil price volatility. Analyst sentiment is cautious with 27% buy ratings versus 55% hold, suggesting limited near-term upside potential from current levels.
Trailing returns across standard periods
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →